CRKL and chronic myelogenous leukemia, BCR-ABL1 positive: In fact, the phosphorylation of CrkL at Y207 is considered an indicator of cancer remission in Chronic Myeloid Leukemia patients after imatinib treatment12, and previously was the only identified phospho-site known to regulate CrkL activity.